Biohit Oyj Class BOMXHEX: BIOBV

Constitutive meeting of Biohit Oyj's Board of Directors

· Issued by Biohit Oyj Class B
English Finnish Published: 2026-06-05 17:00:00 CEST Biohit Oyj - Other information disclosed according to the rules of the Exchange Constitutive meeting of Biohit Oyj's Board of Directors

Biohit Oyj, Other information disclosed according to the rules of the Exchange, June 5, 2026 at 6:00 pm local time (EEST)

Biohit Oyj's Board of Directors has in its meeting on June 5, 2026 elected Professor Kari Syrjänen as the Chairman of the Board of Directors.

Syrjänen's strong scientific expertise supports the work of the Board of Directors and the development of the company.

Additional information:
CEO Jussi Hahtela, Biohit Oyj

tel. +358 9 773 861

investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is "Innovating for Health" - we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

Company News Subscribe European Market Activity Nasdaq Europe
© 2026, Nasdaq, Inc. All Rights Reserved.

Earlier from Biohit Oyj Class B

All Biohit Oyj Class B news releases